Antitumor agents bound to silica nanoparticles : potential technology for the remediation of malignant tumors
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Commercially widely used antitumor agents such as hydroxy urea, 6-mercaptopurine monohydrate,cytosine arabinoside, cyclophosphamide monohydrate and uracil were reacted with 3-(triethoxysilyl)propyl isocyanate and the product hydrolyzed to give silica nanoparticles bound antitumor agents ranging from 10 nm to micron-sized aggregates. The silyl isocyanate derivative was also reacted neat with water to give hybrid organicsilica nanoparticles containing -CH2-CH2-CH2-NH-COOH or the corresponding decarboxylated propylamine groups depending on solvent and temperature employed. In vitro tests these functionalized silica nanoparticles were effective in the treatment of malignant tumor cells but had little or no effect on normal cells. Malignant human lung, ovarian, melanoma, CNS(Central nervous system) and colon tumor cells were used in this research. The use of silica as a carrier medium in the present research serves as a model material due to its ready functionalization via silation. The proof of concept established by the results suggests that the technique may be applied to other, more biocompatible carrier nanoparticles.
Abstract
Commercially widely used antitumor agents such as hydroxy urea, 6-mercaptopurine monohydrate,cytosine arabinoside, cyclophosphamide monohydrate and uracil were reacted with 3-(triethoxysilyl)propyl isocyanate and the product hydrolyzed to give silica nanoparticles bound antitumor agents ranging from 10 nm to micron-sized aggregates. The silyl isocyanate derivative was also reacted neat with water to give hybrid organicsilica nanoparticles containing -CH2-CH2-CH2-NH-COOH or the corresponding decarboxylated propylamine groups depending on solvent and temperature employed. In vitro tests these functionalized silica nanoparticles were effective in the treatment of malignant tumor cells but had little or no effect on normal cells. Malignant human lung, ovarian, melanoma, CNS(Central nervous system) and colon tumor cells were used in this research. The use of silica as a carrier medium in the present research serves as a model material due to its ready functionalization via silation. The proof of concept established by the results suggests that the technique may be applied to other, more biocompatible carrier nanoparticles.
참고문헌 (17)
- Higashi, Sohei (Nanocarrier Co., Ltd., Japan), , Farumashia, 38(4), pp.345~346 (2002)
- (Fannin Bioscience, Inc., USA) PCT Int. Appl. WO 00 61,788 (C1. C12Q), 19 Oct 2000, US Appl. 291,234,13 Apr 1999; 65pp. (Eng), "Xu, Jingya", ~, pp.WO 00 61,788 (C1. C12Q) (1999)
- Rihova, B., "(Polymer Materials Research Group, University of Gent, 9000 Ghent, Belg.)", Proc. Int. Symp. Controlled Release Bioact. Mater, 통권 : 26, pp.627~628 (1999)
- PCT Int. Appl. WO 99 00,113 (C1. A61K9, "22), 7 Jan 1999, US Appl, 926,155,9 Sep 1997; 175pp. (Eng).", Deggi, Neil P, 1999, PCT Int. Appl. WO 99 00,113 (C1. A61K9[DOI]
- (Ramot-University Authority for Applied Research and Industrial Development Ltd., Israel) PCT Int. Appl. WO 02 07,670 (C1. A61K), 31 Jan 2002, US Appl. 668,714, 22 Sep 2000; 66pp. (Eng), "Lavi, Sara", ~, pp.PCT Int. Appl. WO 02 07,670 (C1. A61K) (2002)
- (Ramot-University Authority for Applied Research and Industrial Development Ltd., Israel) PCT Int. Appl. WO 02 07,671 (C1. A61K), 31 Jan 2002, US Appl. 668,713, 22 Sep 2000; 73pp. (Eng), "Lavi, Sara", ~, pp.PCT Int. Appl. WO 02 07,671 (C1. A61K) (2002)
- (Lavipharm Laboratories Inc., USA) PCT Int. Appl. WO 02 54,997 (C1. A61F13, "00), 18 Jul 2002, US Appl. PV260, 587, 9 Jan 2001; 20pp. (Eng)", Fotinos, Spiros, 2002, PCT Int. Appl. WO 02 54,997 (C1. A61F13[DOI]
- Angioteth Pharmaceuticals Inc., Can.) PCT Int. Appl. WO 02 72,150 (C1. A61K47, "48), 19 sep 2002, US Appl. PV337,935, 7 N", Liggins, Richard, 2002, PCT Int. Appl. WO 02 72,150 (C1. A61K47[DOI]
- Nizard, Philippe, "(Deparetment d’Ingenierie et d’Etudes des Proteines, CEA-Saclay, 91191 Gif-sur-Yvette, FR.)", Journal de la Societe de Biologie, 195(3), pp.229~234 (2001)
- (Genesegues, Inc., USA) PCT Int. Appl. WO 01 64,164 (C1. A61K), 7 Sep 2001, US Appl. PV185,282, 28 Fed 2000; 70 pp. (Eng), "Unger, Gretchen M", ~, pp.PCT Int. Appl. WO 01 64,164 (C1. A61K) (2000)
- Burman, Anand C, "(Dabur Research Foundation, India) U.S. US 6,365,191 (C1. 424-489; A61K9", 14), 2 Apr 2002, IN Appl. 2000, pp.2000, ~
- Maitra, Amarnath, "(Dabur Research Foundation; Delhi University, India) U.S. US 6,322,817 (C1. 424-489; A61K47", 30), 27 Nov 2001, IN Appl. 1999, pp.1999, ~
- Fukumori, Yoshinobu, "(Faculty of Pharmaceutical Sciences and High Technology Research Center, Kobe Gakuin University, Kove, Japan 651-2180)", Int. Conf. Process. Mater. Prop. Proc., 통권 : 2, pp.453~458 (2000)
- (Bioalliance Pharma (S.A.); Monza Da Silverira, Airton, Fr.) PCT Int. Appl. WO 99 43,359 (C1. A61K47, "48), 2 Sep 1999, FR Appl. 1998", 2,429, 27 Feb 1998; 56 pp. (Fr), pp.1999, ~[DOI]
- Balland, Olivier, "(Laboratorie de Biophysique, Museum National Histoire Naturelle, 75231 Paris, Fr.)", NATO ASI Ser., Ser. A, 290, pp.131~142 (1996)
- Jain, S., "(Department of Pharmaceutical Sciences, DR. H. S. Gour University, Sagar, 470003 India)", Proc. Int. Symp. Controlled Release Bioact. mater., 통권 : 24, pp.857~858 (1997)
- R. Partch, , pp.27~40 (2003), Kluwer Academic publishers